A Podcast Discussion on the Intracranial Efficacy of Antibody–Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain Metastases
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
A Podcast Discussion on the Intracranial Efficacy of Antibody–Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain Metastases ; day:18 ; month:12 ; year:2024 ; pages:1-14
Oncology and Therapy ; (18.12.2024), 1-14
- Creator
-
Johnson, Melissa L.
Lin, Jessica J.
Boire, Adrienne
Khandekar, Melin J.
Yu, Helena A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40487-024-00315-1
- URN
-
urn:nbn:de:101:1-2503010644301.550729913126
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:33 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Johnson, Melissa L.
- Lin, Jessica J.
- Boire, Adrienne
- Khandekar, Melin J.
- Yu, Helena A.
- SpringerLink (Online service)
Other Objects (12)
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Antibody–drug conjugates as an emerging therapy in oncodermatology
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Research progress of antibody–drug conjugates in gynecologic cancer
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Antibody–drug conjugates as an emerging therapy in oncodermatology
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Research progress of antibody–drug conjugates in gynecologic cancer
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Antibody–drug conjugates as an emerging therapy in oncodermatology
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Research progress of antibody–drug conjugates in gynecologic cancer
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors